|
|
|
| The Value of Serum OPG and TRAIL in Preoperative Evaluation of Lymphatic Metastasis of Esophageal Cancer |
| TAN Zhigang, JIANG Guojun, DAI Ting, et al |
| Yixing People's Hospital, Jiangsu Yixing 214200, China |
|
|
|
|
Abstract Objective: To investigate the relationship between serumosteoprotegerin (OPG), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and lymphatic metastasis of esophageal cancer, and to explore its value in preoperative evaluation of lymphatic metastasis of esophageal cancer. Methods: 48 patients with esophageal cancer were selected as the study object, among which 24 patients with lymph node metastasis confirmed by postoperative pathology were the study group, and 24 patients without lymph node metastasis were the control group. The serum levels of OPG and trail were detected by ELISA and caspase protein was detected by Western blot. ROC curve was used to analyze serum OPG, trail and trail / OPG ratio for preoperative evaluation of esophageal cancer with or without lymphatic metastasis. Results: The serum OPG level in esophageal cancer patients with lymphatic metastasis was significantly higher than those without lymph node metastasis, whereas the serum TRAIL level and the ratio of TRAIL/OPG were significantly lower (P＜0.05). The best cut-off points of serum OPG and TRAIL for the diagnosis of esophageal cancer with lymphatic metastasis were ＞0.495pmoL/mL and＜0.485pmoL/mL, respectively, with the diagnostic sensitivity, specificity and accuracy of 91.7%, 37.5%, 64.6% and 75.0%,58.3%,67.0%, respectively. The sensitivity, specificity and accuracy of TRAIL/OPG ratio at the best cut-off point (＜0.693) for the diagnosis of esophageal cancer with lymphatic metastasis were 79.2%,83.3% and 81.3%, respectively. Conclusion: TRAIL-mediated apoptotic pathway may be related to lymphatic metastasis of esophageal cancer, thus TRAIL/OPG ratio can be a promising auxiliary clinical index for evaluating lymphatic metastasis of esophageal cancer before surgery.
|
|
|
|
|
|
[1] Tuthill M H, Montinaro A, Zinngrebe J, et al. TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells[J]. Oncogene, 2015, 34(16):2138~2144.
[2] Ke R, Vishnoi K, Viswakarma N, et al. Involvement of AMP-activated protein kinase and death receptor 5 in TRAIL-berberine-induced apoptosis of cancer cells[J]. Scientific Reports, 2018, 8(1):5521.
[3] Ma Z , Fan C , Yang Y , et al. Thapsigargin sensitizes human esophageal cancer to TRAIL-induced apoptosis via AMPK activation[J]. Scientific Reports, 2016, 6:35196.
[4] Thapa B, Bahadur K R,et al. Novel targets for sensitizing breast cancer cells to TRAIL-induced apoptosis with siRNA delivery[J]. International Journal of Cancer, 2017, 142(3).
[5] 陈明治,蒋国军,谈永飞,等.护骨素和可溶性核因子кB受体活化因子配体在非小细胞肺癌诊断和鉴别诊断中的意义[J].中国肿瘤临床与康复,2015,(3):261~263.
[6] Heitzer E, Perakis S, Geigl J B, et al. The potential of liquid biopsies for the early detection of cancer[J]. npj Precision Oncology, 2017, 1(1):36. |
|
|
|
2020, Vol. 26 
